At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 84 enrolled
Drug / intervention
LHW090 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Two Part Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Renal Safety, Tolerability and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function on Angiotensin Receptor Blockers
In Brief
A Phase 2 clinical trial evaluating LHW090 and Placebo for Chronic Kidney Disease (CKD). Completed, enrolled 84 participants across 12 sites in 2 countries.
Detailed Summary
This was a randomized, double-blind, parallel group, placebo-controlled study, in two sequential parts that evaluated the renal safety, tolerability and pharmacokinetics of LHW090 in patients with moderately impaired renal function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease (CKD)
CountriesGermany, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartMar 2017
Primary CompletionOct 2018
TodayJul 2026
First PostedFeb 9, 2016
Enrollment StartMar 10, 2017
Primary CompletionOct 11, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.4 years ago
Interventions
LHW090drug
LHW090 is orally administered
Placebodrug
Matching placebo of LHW090